Updated August 2026
SNAP-8 Dosage: Topical Concentration, Evidence, and Research Protocol
Research note: SNAP-8 is a trade name for acetyl octapeptide-3 (Ac-EEMQRRAD-NH₂). 3%–10% of the 0.05% supplier solution = 0.0015%–0.005% pure peptide (15–50 mcg/g). Manufacturer study: 10% solution BID × 28 d (~35% mean wrinkle-depth reduction). No FDA drug dose · no validated injectable dose. Percentages refer to premix, not pure powder.
SNAP-8 is marketed as a cosmetic ingredient, not an approved drug. The critical dosage distinction is between supplier solution percentage, pure peptide percentage, and applied mass on skin.
Calling a formula '10% SNAP-8' usually means 10% of a solution that is itself 0.05% peptide — yielding 0.005% pure peptide (50 mcg/g), not 10% pure peptide.
Human evidence is limited to small manufacturer and combination-product studies on intact or microneedle-delivered skin. Online lyophilized vial injection schedules have no human pharmacokinetic or safety basis.
SNAP-8 dosage in 30 seconds
| Question | Evidence-based answer |
|---|---|
| FDA drug dose | None — cosmetic ingredient |
| Supplier use level | 3%–10% of 0.05% solution |
| Pure peptide in product | 0.0015%–0.005% w/w |
| mcg per gram at 0.005% | 50 mcg/g |
| Manufacturer regimen | 10% solution BID × 28 d |
| Lower report | 3% solution · mean −7.1% depth |
| Injectable dose | None validated |
| Proposed RCT | 0.0015 / 0.003 / 0.005% BID × 12 wk |
Compound identity
Reproducible records require full sequence, N-acetyl and C-amidated termini, intact mass, counterion, peptide assay, and related-substance profile.
Identity gate
SNAP-8 vs Argireline · botulinum toxin · injection vials
This page's subject — Ac-EEMQRRAD-NH₂ cosmetic octapeptide
MW ~1075.2 Da · CAS 868844-74-0 · trade name for dilute aqueous cosmetic ingredient. Topical route only in human evidence.
Solution, pure peptide, and finished product
Three quantities must stay separate: pure peptide, SNAP-8 Peptide Solution C (0.05% active), and finished cosmetic percentage.
Concentration math
3–10% supplier solution → 0.0015%–0.005% pure peptide
SNAP-8 Peptide Solution C is 0.05% active peptide. Finished product uses 3%–10% of that solution, not 3%–10% pure powder.
| Solution in formula | Pure peptide % | mcg/g | Solution / 100 g | Peptide / 100 g |
|---|---|---|---|---|
| 3% of 0.05% premix | 0.0015% | 15 mcg/g | 3 g | 1.5 mg |
| 6% of 0.05% premix | 0.003% | 30 mcg/g | 6 g | 3.0 mg |
| 10% of 0.05% premix | 0.005% | 50 mcg/g | 10 g | 5.0 mg |
Formula: pure % = solution % × 0.0005. Example: 10% × 0.0005 = 0.005%.
Concentration and application mathematics
Unit converter
Supplier solution % → pure peptide % → mcg/g
Converted
0.0050% pure peptide
0.05 mcg/g
Applied topical mass calculator
Application calculator
Placed-on-skin micrograms = concentration × grams applied
0.00 mcg placed per application
(0.05 mcg/g × 0.05 g) — placed dose, not absorbed dose
| Pure % | 0.05 g | 0.25 g | 0.50 g |
|---|---|---|---|
| 0.0015% | 0.75 mcg | 3.75 mcg | 7.5 mcg |
| 0.003% | 1.5 mcg | 7.5 mcg | 15 mcg |
| 0.005% | 2.5 mcg | 12.5 mcg | 25 mcg |
Placed-on-skin micrograms are not absorbed dose. Vehicle, barrier condition, and residence time determine tissue exposure.
Regulatory context
U.S. cosmetics are not FDA premarket-approved (except color additives). SNAP-8 has supplier-recommended formulation range but no regulator-reviewed therapeutic schedule. Cosmetic use level ≠ prescription dose.
Dosage in human research
Human evidence
Manufacturer topical · combination serums · microneedle patches
| Study | Concentration | Schedule | Finding |
|---|---|---|---|
| Lipotec manufacturern=17 women | 10% of 0.05% solution0.005% (50 mcg/g) | BID × 28 d periocular | Mean wrinkle depth −34.98%; max individual ~63% |
| Moy 2022 (secondary)n=Prior supplier data | 3% of 0.05% solution0.0015% (15 mcg/g) | BID × 28 d split-face | Mean −7.1%; max 38% wrinkle depth |
| Shin 2024 microneedlen=21 completers | 0.03% in matrix + 3 co-activesNot isolatable | Overnight daily × 14 d then q3d to d28 | Combination patch favored — SNAP-8 mass/patch not reported |
| Avcil 2020 microneedlen=Industry-funded | Undisclosed multi-peptide patchNot reported | 12 weeks | Fine lines −25.8% — cannot attribute to SNAP-8 alone |
| Moy 2022 serumn=31 completers | Multi-ingredient serumUndisclosed | BID × 12 wk whole face | Open-label — product-level, not monotherapy |
| Ji 2020 analyticaln=4 patches | 1.42 mg patch extracted76.9 ± 8.6 ng SNAP-8 | QC method only | Matrix-matched LC-MS/MS — not efficacy dose |
Microneedle versus conventional topical
Route comparison
Conventional topical vs microneedle matrix — not dose-equivalent
- Conventional topical max
- 0.005% pure · 50 mcg/g
- Shin 2024 matrix
- 0.03% SNAP-8 + 3 co-actives
- Mass per patch
- Not reported (clinical) · 76.9 ng analytical QC
- Route equivalence
- Not equivalent — barrier disruption changes delivery
- Attribution
- Combination products cannot establish monotherapy dose
Evidence hierarchy
Evidence tiers
From approved drug label to unsupported injection claims
| Tier | Source | Status |
|---|---|---|
| Tier A — Approved drug label | None | No FDA drug dose for SNAP-8 |
| Tier B — Controlled peptide-specific trial | None adequate yet | No optimal concentration established |
| Tier C — Manufacturer human studies | 0.0015% and 0.005% topical | Reconstructable concentration · limited independence |
| Tier D — Combination products | Microneedle patches/serums | Finished-product signals · not isolated SNAP-8 |
| Tier E — In-vitro/analytical | SNARE assays · LC-MS/MS | Mechanism and QC only |
| Tier F — Supplier guidance | 3%–10% of 0.05% solution | Formulation convention |
| Tier G — Vial/injection online | Fixed mcg SC claims | No human injection record |
Supplier, market, and unsupported protocols
Protocol map
Supplier range · market serums · proposed RCT · unsupported injection
- Dose / concentration
- 10% of 0.05% solution
- 0.005% · 50 mcg/g
- Frequency
- Twice daily × 28 d
- Evidence basis
- Lipotec technical brochure · 17 women
Cumulative placed-on-skin exposure
Cumulative exposure
Placed-on-skin micrograms over a treatment period
140.0 mcg total placed (0.140 mg)
5 mcg/day · 0.005% · 0.05 g/app · BID × 28 d
Clinical versus market protocols
Evidence split
Reconstructable topical studies vs market and injection claims
Human topical evidence
Manufacturer + secondary reports · combination studies
- Pure peptide range
- 0.0015%–0.005% w/w
- Supplier solution
- 3%–10% of 0.05% premix
- Frequency
- Twice daily in manufacturer reports
- Duration
- 28 days in key studies
- Injectable dose
- None established
Market / unsupported practice
Undisclosed serums · vial injection claims
- Serum concentration
- Often undisclosed
- '10% SNAP-8' error
- May mean 10% premix ≠ 10% pure peptide
- Injection vials
- 10 mg lyophilized · no human PK
- Microneedling DIY
- Different route · not authorized by topical data
- Pump/drop dose
- Unvalidated without gravimetric testing
Preclinical and mechanistic concentrations
Preclinical anchors
SNARE assays and cell baths — bypass intact skin
| Model | Dose | Outcome |
|---|---|---|
| SNARE complex | Not fully reported | Reduced assembly/stability — manufacturer assay |
| Chromaffin cells | 100 µM (~107.5 mcg/mL) | Catecholamine release modulation — bypasses skin |
| Primary neurons | 0.75–1.5 mM | Dose-dependent glutamate release reduction |
| Argireline lineage | Hexapeptide data | Supports SNARE-mimetic hypothesis · not SNAP-8 dose |
100 µM–1.5 mM cell bath concentrations bypass stratum corneum — not predictive of intact-skin topical activity.
Mechanism relevant to dosage
Proposed SNARE-complex competition (SNAP-25 mimicry) differs from botulinum toxin's enzymatic cleavage. ~1075 Da hydrophilic peptide faces passive penetration limits through intact skin.
Safety, tolerability, and monitoring
Safety
Tolerability in small studies · topical risks · product quality
- Reported tolerability
- 2024 microneedle study: no AEs in 21 completers/28 d. 12-wk serum: 2/31 irritation not product-related per investigators.
- Plausible topical risks
- Burning, stinging, erythema, scaling; ocular exposure if applied near lid margin; contact reaction to vehicle/preservative.
- Facial function
- Monitor for asymmetry, ptosis, focal weakness — proposed mechanism involves SNARE pathway though topical muscle exposure unproven.
- Product quality
- Raw powder ≠ cosmetic-grade. Breindahl-style vial underpotency and impurities risk with unqualified material.
Complete proposed topical research protocol
Split-face RCT: 180 participants · 0.0015%, 0.003%, or 0.005% pure peptide vs vehicle · 2 mg/cm² · 0.05 g per side · BID × 12 weeks · 3D profilometry primary endpoint · Week 16 persistence follow-up. No microneedles, injection, or intentional UV.
Proposed split-face RCT
180 participants · 0.0015 / 0.003 / 0.005% · BID × 12 weeks · 2 mg/cm²
Cumulative placed dose at 0.05 g per side · twice daily
| Arm | Pure % | mcg/app | mcg/day | 12-wk total |
|---|---|---|---|---|
| Vehicle | — | — | — | — |
| Low | 0.0015% | 0.75 | 1.5 | 126 mcg |
| Mid | 0.003% | 1.5 | 3 | 252 mcg |
| High | 0.005% | 2.5 | 5 | 420 mcg |
Week 16 persistence visit · 3D profilometry primary · no microneedling or injection · vehicle-controlled split-face design.
Claims versus evidence
Claim checker
Marketing statements vs evidence
“10% SNAP-8 means 10% pure peptide in the cream”
False
10% of 0.05% solution = 0.005% pure peptide. Ten percent pure would be 2,000× more concentrated.
Dosage evidence ladder
Confidence ladder
What is known vs uncertain about SNAP-8 dosage
| Question | Evidence | Confidence |
|---|---|---|
| 0.05% premix composition | Supplier documentation | Moderate–high |
| 3–10% → 0.0015–0.005% math | Direct arithmetic | High |
| 0.005% used topically in humans | Manufacturer study n=17 | Moderate |
| 0.0015% used topically | Secondary supplier-linked report | Moderate–low |
| vs vehicle wrinkle improvement | Small manufacturer data | Low |
| 0.005% > 0.0015% efficacy | No head-to-head RCT | Very low |
| Reaches neuromuscular junction | Not demonstrated | Very low |
| Microneedle combination products | Controlled/prospective studies | Moderate for product |
| Injectable human dose | None | Absent |
| Long-term daily safety | Limited surveillance | Low |
Bottom line
'3%–10% SNAP-8' refers to a 0.05% premixed ingredient, not pure peptide. Reconstructable conventional topical human range: 0.0015%–0.005% pure acetyl octapeptide-3, usually twice daily for 28 days in manufacturer reports.
Independent vehicle-controlled concentration-ranging replication is still missing. The best next study is a blinded split-face trial at 0.0015 / 0.003 / 0.005% with measured application mass — not vial-based injection.
3–10% premix · 15–50 mcg/g pure · BID × 28 d manufacturer · no injectable dose.
Frequently asked questions
What percentage was used in the best-known study?
10% of a 0.05% supplier solution = 0.005% pure peptide, or 50 mcg/g, applied twice daily for 28 days periocularly.
Is 10% SNAP-8 the same as 10% pure peptide powder?
No. Ten percent pure peptide would be about 2,000 times more concentrated than 0.005%.
What is the documented topical range?
0.0015%–0.005% pure peptide, from 3%–10% of the 0.05% supplier solution.
How much peptide is in one gram at 0.005%?
Fifty micrograms.
Is there an injectable SNAP-8 dose?
No validated human injection regimen, pharmacokinetic model, or clinical dose-development record exists.
Is SNAP-8 topical Botox?
No. Different substances, mechanisms, routes, evidence, and regulatory status.
Does SNAP-8 penetrate intact skin?
Size and hydrophilicity make passive penetration challenging. Human dermal PK for conventional serum is not adequately established.
Can it be used with microneedling?
That is a different delivery route requiring a separately qualified device-product protocol.
Does more peptide always work better?
Not demonstrated. No adequate head-to-head randomized concentration trial.
Is a pump or drop a scientific dose?
Only if delivered mass and variability are measured gravimetrically.
References
Lipotec
SNAP-8 technical brochure0.05% solution · 3–10% use · 17-woman study.
Moy M et al.
Peptide-pro complex serum 20223% supplier-solution secondary summary.
Shin JY et al.
Dissolving microneedle patch 20240.03% matrix combination · n=21.
FDA
Authority over cosmeticsCosmetics not premarket-approved.
Ji Y et al.
LC-MS/MS patch QC 202076.9 ng analytical measurement.
Blanes-Mira et al.
Argireline SNARE mechanismHexapeptide lineage · not SNAP-8 dose.